Treatment Satisfaction and Health-Related Quality of Life in Iraqi Patients with Rheumatoid Arthritis Receiving Biologic Therapy; Rituximab
DOI:
https://doi.org/10.31351/vol33iss(4SI)pp230-235Keywords:
Treatment satisfaction with RituximabAbstract
The exact mechanism of action and which rheumatoid arthritis (RA) patients might benefit from Rituximab (RTX) are still questionable. One of the key elements in assessing the performance of a healthcare facility is patient satisfaction, which is a measure of how satisfied a patient is with the medical care he receives. This study aimed to evaluate the health-related quality of life and treatment satisfaction and their association with the responsiveness to RTX in RA patients. A cross-sectional study was conducted at the Center of Rheumatology in Baghdad- Iraq. The study enrolled 90 patients diagnosed with RA and receiving RTX intravenous infusion, for at least six months. The 28-joints disease activity score (DAS28) and clinical disease activity index (CDAI) were used to assess disease activity and RTX response. RA Impact of Disease (RAID) and Treatment Satisfaction Questionnaire for Medication (TSQM) were used to assess the health-related quality of life and treatment satisfaction, respectively. A total of 90 patients were enrolled in the current study and were divided into two groups (the RTX responders group included 50 patients and the RTX non-responders group included 40 patients) according to DAS28 and CDAI assessment. The patients in the responders group had a significantly better quality of life according to the RAID score (P-value<0.001), the effectiveness, convenience, and global satisfaction were significantly higher in the responders group compared to the non-responders group (P-values were <0.001 for all). There were significant negative correlations between the effectiveness, convenience, and global satisfaction with RAID, CDAI, and DAS28. Better health-related quality of life and satisfaction were achieved among RTX responders compared to others, some satisfaction parameters were affected by the history of RA and duration of disease
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
He P, Zhang Z, Liao W, Xu D, Fu M, Kang Y. Screening of Gene Signatures for Rheumatoid Arthritis and Osteoarthritis Based on Bioinformatics Analysis. Molecular medicine reports. 2016;14(2):1587-93.
Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, et al. Signaling Pathways in Rheumatoid Arthritis: Implications for Targeted Therapy. Signal Transduction and Targeted Therapy. 2023;8(1):68.
Otón T, Carmona L. The epidemiology of established rheumatoid arthritis. Best Practice & Research Clinical Rheumatology. 2019;33(5):101477.
Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, et al. Global, Regional, and National Burden of Rheumatoid Arthritis, 1990–2020, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023;5(10):594-610.
Thamer W. Study of Some Immunological Effects of Methotrexate in People with Rheumatoid Arthritis. Al-Qadisiyah Journal Of Pure Science. 2019;24(2).
Fatel ECdS, Rosa FT, Simão ANC, Dichi I. Adipokines in rheumatoid arthritis. Advances in Rheumatology. 2018;58(1):25.
Gamal RM, Mahran SA, Abo El Fetoh N, Janbi F. Quality of Life Assessment in Egyptian Rheumatoid Arthritis Patients: Relation to Clinical Features and Disease Activity. The Egyptian Rheumatologist. 2016;38(2):65-70.
Sepriano A, Kerschbaumer A, Smolen JS, Van Der Heijde D, Dougados M, Van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases. 2020;79(6):760-70.
Hua C, Buttgereit F, Combe B. Glucocorticoids in Rheumatoid Arthritis: Current Status and Future Studies. RMD Open. 2020;6(1):536.
Crofford LJ. Use of NSAIDs in Treating Patients with Arthritis. Arthritis Research & Therapy. 2013;15(3):2.
Mohammed MM, Al-Shamma K, Jasim N. Evaluation of the anti-inflammatory effect of metformin as adjuvant therapy to NSAID (meloxicam) in patients with knee osteoarthritis. Int J Sci Nature. 2014;5:277-82.
Baqer MS, Mohammed MM. Evaluation of The Anti-Inflammatory Effect of Curcumin as An Additive Therapy to Meloxicam in Management of Knee Osteoarthritis. International Journal of Drug Delivery Technology. 2022;12:310-5.
Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. Journal of the American Society of Nephrology. 2021;32(10):2652-63.
Oldenburg P. Rituximab. Reference Module in Biomedical Sciences. Elsevier. 2018.
Tareq Abdulazeez S, Salman S, I Goria F. Efficacy, Safety and Predictors of Response to Rituximab in Treatment of Iraqi Patients with Active Rheumatoid Arthritis. Al-Anbar Medical Journal. 2019;15(1):16-21.
Cohen MD, Keystone E. Rituximab for Rheumatoid Arthritis. Rheumatol Ther. 2015;2(2):99-111.
Manzoor F, Wei L, Hussain A, Asif M, Shah SIA. Patient Satisfaction with Health Care Services; An Application of Physician's Behavior as a Moderator. Int J Environ Res Public Health. 2019;16(18).
Miladi S, Belhadj W, Boussaa H, Yasmine M, Leith Z, Abdelghani KB, et al. Patient satisfaction with medication in rheumatoid arthritis: an unmet need. Reumatologia. 2023;61(1):38-44.
Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. DAS28 Best Reflects the Physician's Clinical Judgment of Response to Infliximab Therapy in Rheumatoid Arthritis Patients: Validation of the DAS28 Score in Patients under Infliximab Treatment. Arthritis research & therapy. 2005;7:1-9.
Salaffi F, Di Carlo M, Farah S, Marotto D, Atzeni F, Sarzi-Puttini P. Rheumatoid Arthritis Disease Activity Assessment in Routine Care: Performance of the Most Widely Used Composite Disease Activity Indices and Patient-Reported Outcome Measures. Acta Biomed. 2021;92(4):2021238.
Thiele K, Albrecht K, Zink A, Aringer M, Karberg K, Späthling-Mestekemper S, et al. Is the Rheumatoid Arthritis Impact of Disease (RAID) Score A Meaningful Instrument for Other Inflammatory Rheumatic Diseases? A Cross-ectional Analysis of Data from the German National Database. RMD Open. 2022;8(2):2342.
Holten K, Paulshus Sundlisæter N, Sexton J, Nordberg LB, Uhlig T, Kvien TK, et al. Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in Relation to Flares in Disease Activity. RMD Open. 2024;10(1).
Liberato ACS, São João TM, Jannuzzi FF, Landaas EJ, Wongchareon K, Rodrigues RC. Treatment Satisfaction Questionnaire for Medication (TSQM version 1.4): Ceiling and Floor Effects, Reliability, and Known-Group Vlidity in Brazilian Outpatients with Hypertension. Value in Health Regional Issues. 2020;23:150-6.
Shahrbabaki ME, Ahmadipour H, Yousefi N, Divsalar P. Treatment Satisfaction Questionnaire for Medication (TSQM Version II): A Psychometric Properties Analysis. 2021.
Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clinical and Experimental Rheumatology-Incl Supplements. 2011;29(6):991.
Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M. Predictive factors of Rituximab Response in Rheumatoid Arthritis: Results from A French University Hospital. Arthritis Care Res (Hoboken). 2013;65(4):648-52.
Abdul K, David Lloyd S, Mike B. Smoking, Rheumatoid Factor Status and Responses to Rituximab. Annals of the Rheumatic Diseases. 2012;71(9):1587.
Rigby W, Ferraccioli G, Greenwald M, Zazueta‐Montiel B, Fleischmann R, Wassenberg S, et al. Effect of Rituximab on Physical Function and Quality of Life in Patients with Rheumatoid Arthritis Previously Untreated with Methotrexate. Arthritis care & research. 2011;63(5):711-20.
Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. The Journal of rheumatology. 2008;35(1):20-30.
Taylor PC, Ancuta C, Nagy O, de la Vega MC, Gordeev A, Janková R, et al. Treatment satisfaction, patient preferences, and the impact of suboptimal disease control in a large international rheumatoid arthritis cohort: SENSE study. Patient preference and adherence. 2021:359-73.
Volkmann ER, Agrawal H, Maranian P, Furst DE. Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clinical Medicine Insights: Therapeutics. 2010;2:CMT. S5566.
Covelli M, Sarzi-Puttini P, Atzeni F, Macchioni P. Safety of Rituximab in Rheumatoid Arthritis. Reumatismo. 2010;62(2):101-6.
Sebastiani M, Anelli MG, Atzeni F, Bazzani C, Farina I, Fedele AL, et al. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. Joint Bone Spine. 2014;81(6):508-12.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
